Candel therapeutics appoints mace l. rothenberg, md, as senior advisor to the chief executive officer

Needham, mass., oct. 19, 2021 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has appointed mace l. rothenberg, md, as a senior advisor to its president and chief executive officer, paul peter tak, md, phd, fmedsci. dr. rothenberg, an industry veteran with more than 30 years of experience across government, academia and industry, will help support the company's continued growth and acceleration.
CADL Ratings Summary
CADL Quant Ranking